ArticleTranslational gastroenterology and hepatology2026
Monocyte to apolipoprotein A1 ratio as a novel biomarker for hepatocellular carcinoma: a retrospective study.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The ratio of monocyte to apolipoprotein A1 (MAR) has emerged as a potential diagnostic marker for various chronic conditions, yet its utility in hepatocellular carcinoma (HCC) remains unexplored. This retrospective study aimed to evaluate the MAR's predictive capacity in HCC diagnosis and differentiation from hepatitis B virus (HBV) infection. Methods: A total of 1,350 participants were enrolled, including 270 HCC patients, 540 HBV patients, and 540 healthy controls. Hematological parameters including monocyte counts and apolipoprotein A1 levels were retrospectively collected from electronic medical records. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal cut-off values and area under the curve (AUC). Multivariate logistic regression was used to identify independent predictor of HCC. Correlation analysis was conducted to explore associations between MAR and other clinical parameters. Results: MAR level was the highest in the HCC, followed by HBV group, and the lowest in the healthy controls (P<0.001). ROC analysis revealed MAR's discriminative capacity (AUC =0.829 for HCC Conclusions: MAR is a potential new indicator for differential diagnosis of HCC and HBV, and also an independent risk factor for HCC. The biomarker's dual reflection of inflammatory and metabolic pathways offers unique diagnostic value, warranting prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.